Literature DB >> 12753909

Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215.

Ratna K Vadlamudi1, Aysegul A Sahin, Liana Adam, Rui An Wang, Rakesh Kumar.   

Abstract

To elucidate the molecular mechanisms by which human epidermal growth factor receptor/heregulin (HER2/HRG) influence the migratory potential of breast cancer cells, we have used phospho-specific antibodies against c-Src kinase and focal adhesion kinase (FAK). This study establishes that HER2/HRG signaling selectively upregulates Tyr phosphorylation of c-Src at Tyr-215 located within the SH2 domain, increases c-Src kinase activity and selectively upregulates Tyr phosphorylation of FAK at Tyr-861. HER2-overexpressing tumors showed increased levels of c-Src phosphorylation at Tyr-215. These findings suggest that HER2/HRG influence metastasis of breast cancer cells through a novel signaling pathway involving phosphorylation of FAK tyrosine 861 via activation of c-Src tyrosine 215.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12753909     DOI: 10.1016/s0014-5793(03)00404-6

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  40 in total

1.  Insulin-like growth factor-1 receptor signaling increases the invasive potential of human epidermal growth factor receptor 2-overexpressing breast cancer cells via Src-focal adhesion kinase and forkhead box protein M1.

Authors:  Eduardo Sanabria-Figueroa; Siobhan M Donnelly; Kevin C Foy; Meghan C Buss; Robert C Castellino; Elisavet Paplomata; Latonia Taliaferro-Smith; Pravin T P Kaumaya; Rita Nahta
Journal:  Mol Pharmacol       Date:  2014-11-12       Impact factor: 4.436

2.  FERM domain interaction promotes FAK signaling.

Authors:  Jill M Dunty; Veronica Gabarra-Niecko; Michelle L King; Derek F J Ceccarelli; Michael J Eck; Michael D Schaller
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

3.  Α-Dystrobrevin-1 recruits Grb2 and α-catulin to organize neurotransmitter receptors at the neuromuscular junction.

Authors:  Jacinthe Gingras; Marta Gawor; Krzysztof M Bernadzki; R Mark Grady; Peter Hallock; David J Glass; Joshua R Sanes; Tomasz J Proszynski
Journal:  J Cell Sci       Date:  2016-01-14       Impact factor: 5.285

4.  The prognostic role of phospho-Src family kinase analysis in tongue cancer.

Authors:  Ofer Ben-Izhak; Victoria Cohen-Kaplan; Rafael M Nagler
Journal:  J Cancer Res Clin Oncol       Date:  2010-01       Impact factor: 4.553

5.  Phospho-SXXE/D motif mediated TNF receptor 1-TRADD death domain complex formation for T cell activation and migration.

Authors:  Ying-Jie Guan; Zhe Zhang; Chen Yu; Li Ma; Weiling Hu; Li Xu; Jin-Song Gao; Chun-Shiang Chung; Lijuan Wang; Zhong-Fa Yang; Loren D Fast; Alicia S Chung; Minsoo Kim; Alfred Ayala; Shougang Zhuang; Shusen Zheng; Y Eugene Chin
Journal:  J Immunol       Date:  2011-07-01       Impact factor: 5.422

Review 6.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-04-30       Impact factor: 9.867

7.  Loss of hepatocyte ERBB3 but not EGFR impairs hepatocarcinogenesis.

Authors:  Lawrence A Scheving; Xiuqi Zhang; Mary C Stevenson; Michael A Weintraub; Annam Abbasi; Andrea M Clarke; David W Threadgill; William E Russell
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-10-22       Impact factor: 4.052

8.  The dual kinase complex FAK-Src as a promising therapeutic target in cancer.

Authors:  Victoria Bolós; Joan Manuel Gasent; Sara López-Tarruella; Enrique Grande
Journal:  Onco Targets Ther       Date:  2010-06-24       Impact factor: 4.147

9.  Cyanidin-3-glucoside inhibits ethanol-induced invasion of breast cancer cells overexpressing ErbB2.

Authors:  Mei Xu; Kimberly A Bower; Siying Wang; Jacqueline A Frank; Gang Chen; Min Ding; Shiow Wang; Xianglin Shi; Zunji Ke; Jia Luo
Journal:  Mol Cancer       Date:  2010-10-29       Impact factor: 27.401

10.  Activity of the multikinase inhibitor dasatinib against ovarian cancer cells.

Authors:  G E Konecny; R Glas; J Dering; K Manivong; J Qi; R S Finn; G R Yang; K-L Hong; C Ginther; B Winterhoff; G Gao; J Brugge; D J Slamon
Journal:  Br J Cancer       Date:  2009-10-27       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.